Obtaining recombinant arginine deiminase and determining its enzymatic activity using the modified Sakaguchi method
Medical academic journal · 25.06.2026 · 26 (2) · 36-46
DOI: 10.17816/maj677017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical academic journal, online erschienen am 25.06.2026. Verfasst von Elena Yu. Egidarova und 4 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: The development of targeted antitumor drugs is an active area of research, and the identification of new therapeutic targets and the creation of novel agents remain important challenges. Arginine deiminase has been shown to exhibit antiproliferative activity against a number of arginine-auxotrophic tumor cells, making it a promising candidate for antitumor therapy. Therefore, the development of a method for obtaining this recombinant enzyme in a soluble, biologically active form is warranted. AIM: To develop an expression system for the arcA gene of Streptococcus pyogenes M22 in Escherichia coli cells, to produce sufficient quantities of purified recombinant arginine deiminase, and to evaluate its enzymatic activity. METHODS: Recombinant arginine deiminase was produced in E. coli cells. The enzyme was purified using a novel sorbent developed by us for metal-chelate chromatography. Enzyme activity was determined using a method based on a modified Sakaguchi reaction. RESULTS: Cloning of the arcA gene yielded purified, soluble, and enzymatically active recombinant arginine deiminase. It was shown that a pH of 6.6 must be maintained during purification to preserve enzyme activity. Using a modified sorbent for metal-chelate chromatography, an active enzyme with a specific activity of 25 µmol of arginine per minute per mg of protein was obtained. To preserve the activity of the frozen enzyme, it was necessary to add NaCl to a final concentration of 1 M and 2-mercaptoethanol to a final concentration of 0.5 mM. CONCLUSION: The observed high in vitro enzymatic activity of arginine deiminase makes further research promising for the development of a new class of antitumor drugs. The recombinant enzyme, freed from lipopolysaccharide impurities, can be used to assess its cytotoxicity against various cancer cell lines and in in vivo experiments in laboratory animal models.
Zitieren
APA
Egidarova, E. Y., Grudinina, N. A., Zabrodskaya, Y. A., Suvorov, A. N., & Sokolov, A. V. (2026). Obtaining recombinant arginine deiminase and determining its enzymatic activity using the modified Sakaguchi method. Medical academic journal, 26(2), 36-46. https://doi.org/10.17816/maj677017
Vancouver
Egidarova EY, Grudinina NA, Zabrodskaya YA, Suvorov AN, Sokolov AV. Obtaining recombinant arginine deiminase and determining its enzymatic activity using the modified Sakaguchi method. Medical academic journal. 2026;26(2):36-46. doi:10.17816/maj677017
BibTeX
@article{Egidarova2026,
author = {Egidarova, Elena Yu. and Grudinina, Natalia A. and Zabrodskaya, Yana A. and Suvorov, Alexander N. and Sokolov, Alexey V.},
title = {Obtaining recombinant arginine deiminase and determining its enzymatic activity using the modified Sakaguchi method},
journal = {Medical academic journal},
year = {2026},
volume = {26},
number = {2},
pages = {36--46},
doi = {10.17816/maj677017}
}
EUVIMED